Mersana Therapeutics Obtains $35,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ae3572c9-c435-4407-89ee-3612be2ea6c0 - Date
3/2/2015 - Company Name
Mersana Therapeutics - Mailing Address
840 Memorial Drive Cambridge, MA 02139 USA - Company Description
Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs. - Website
http://www.mersana.com - Transaction Type
Venture Equity - Transaction Amount
$35,000,000 - Transaction Round
Series B - Proceeds Purposes
The proceeds will fund the advancement of Mersana’s pipeline of products based on its novel Fleximer antibody-drug conjugate (ADC) platform with its first investigational new drug (IND) filing anticipated later this year. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
